Celltrion Pharm Hosts Cheongju Plant PFS Production Facility Tour for Analysts

Annual Production Capacity of Up to 16 Million Syringes

On May 22, Celltrion Pharm held a tour of its Cheongju plant's PFS (pre-filled syringe) production facility in Ochang-eup, Chungcheongbuk-do, for pharmaceutical and bio analysts from domestic securities firms.

On the 22nd, a tour of the PFS (pre-filled syringe) production facility at Celltrion Pharm's Cheongju plant, located in Ochang, Chungcheongbuk-do, was conducted for domestic securities firms' pharmaceutical and bio analysts. Celltrion Pharm

This event was organized to showcase Celltrion Pharm's global-level production capabilities, which have received GMP (Good Manufacturing Practice) certifications from major pharmaceutical regulatory agencies in Europe, the United States, and Japan. The company also demonstrated its PFS and pen (Auto Injector) training kits, providing participants with a deeper understanding of the products.

The PFS production line occupies three above-ground floors and has a total floor area of 2,315 square meters (approximately 700 pyeong). It covers the entire process, from receiving drug substances (DS), compounding, filling, foreign matter inspection, assembly, labeling, to packaging. The facility can produce up to 16 million syringes annually. Celltrion Pharm plans to build additional production lines and expand its warehouse on a 4,100-pyeong available site at the Cheongju plant. Once the expansion is completed, the production capacity is expected to triple.

Currently, the main products manufactured at the facility are three types of subcutaneous injection (SC) finished pharmaceuticals (DP): two types of PFS and one pen type. The facility's strength lies in its ability to simultaneously produce both the pen type and the highly demanded pre-filled syringe-S type, which are favored for their safety and convenience.

The Cheongju plant's PFS production facility drove Celltrion Pharm's growth by achieving record-high quarterly sales in the first quarter, with contract manufacturing (CMO) sales reaching approximately KRW 18.9 billion, a 37% increase compared to the same period last year. As demand for major SC-type products such as Remsima SC and Yuflyma, which Celltrion supplies to the global market, continues to rise rapidly, the company plans to actively respond to this growing demand by increasing utilization rates and improving production efficiency.

Additionally, Celltrion Pharm aims to continue its growth by expanding its PFS-type finished CMO business for both domestic and international companies targeting the global market. The company expects to establish a differentiated competitive edge in the finished CMO sector by leveraging its production experience with high-quality biopharmaceuticals supplied globally by Celltrion, as well as the quality competitiveness built through global certifications.

A Celltrion Pharm representative stated, "This tour provided an excellent opportunity to thoroughly communicate the strengths of our globally competitive PFS production facilities to domestic pharmaceutical and bio analysts," adding, "As a global pharmaceutical production base manufacturing both chemical and biopharmaceuticals, we will do our utmost to ensure a stable supply of high-quality medicines."